One of the generic Indian pharmaceutical corporations, Hetero Drugs has introduced a biosimilar for the remedy of metastatic colorectal most cancers (mCRC) in India.
The drug referred to as as “Bevacizumab” has been authorized via the Drug Controller General of India because the first-line of remedy for this kind of most cancers and might be advertised below the logo title ‘cizumab’.
‘Hyderabad-based pharmaceutical corporate Hetero Drugs has introduced its biosimilar ‘Bevacizumab’ for the remedy of metastatic colorectal most cancers in India.
The product might be to be had in a unmarried dose vial with two strengths, 100 and 400mg. Hetero will manufacture the medication in the ability founded in Hyderabad.
Dr BPS Reddy, CMD, Hetero Group of Companies stated: “It has been an exciting journey for us in Biologics. Hetero’s Bevacizumab is the third product in our biologics portfolio, after Darbepoetin alfa and Rituximab. We believe CizumabTM will be a cost-effective treatment option to patients in India.”